Walvax Biotechnology's Subsidiary Secures Regulatory Approval for COVID-19 mRNA Vaccine

Stock News

Sep 10

Walvax Biotechnology Co.,Ltd. (300142.SZ) has officially announced that its wholly-owned subsidiary, Yuxi Walvax Biotechnology Co., Ltd., received the "COVID-19 mRNA Vaccine" Drug Registration Certificate from the National Medical Products Administration on September 10, 2026.

Leveraging its mRNA platform technology, the company is positioned to continuously update and iterate new vaccines targeting prevalent strains as recommended by the World Health Organization (WHO) or China's disease control authorities. The newly approved vaccine is designed for use in individuals aged 18 years and above to prevent COVID-19.

This latest approval marks the third-generation COVID-19 mRNA vaccine developed by the company through iterative advancements in its mRNA platform. Since 2020, Walvax Biotechnology Co.,Ltd. has significantly increased its investment in mRNA technology, successfully establishing a leading domestic mRNA technology and industrialization platform. This initiative not only introduces a novel technical route for developing preventive vaccines but also creates a robust foundation for future therapeutic advancements, including tumor vaccines, protein replacement drugs, and In Vivo CAR-T therapies.

Building on its mRNA technology platform, the company has also obtained clinical trial approvals for its respiratory syncytial virus mRNA vaccine and freeze-dried shingles mRNA vaccine. Meanwhile, other therapeutic mRNA drugs are currently advancing through pre-clinical research stages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1158588840"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158588840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158588840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158588840","market":"nz","top_or_hot":-1,"title":"Walvax Biotechnology's Subsidiary Secures Regulatory Approval for COVID-19 mRNA Vaccine","media":"Stock News","content":"<p><b>Walvax Biotechnology Co.,Ltd.</b> (300142.SZ) has officially announced that its wholly-owned subsidiary, Yuxi Walvax Biotechnology Co., Ltd., received the \"COVID-19 mRNA Vaccine\" Drug Registration Certificate from the National Medical Products Administration on September 10, 2026.<br><br>Leveraging its mRNA platform technology, the company is positioned to continuously update and iterate new vaccines targeting prevalent strains as recommended by the World Health Organization (WHO) or China's disease control authorities. The newly approved vaccine is designed for use in individuals aged 18 years and above to prevent COVID-19.<br><br>This latest approval marks the third-generation COVID-19 mRNA vaccine developed by the company through iterative advancements in its mRNA platform. Since 2020, <b>Walvax Biotechnology Co.,Ltd.</b> has significantly increased its investment in mRNA technology, successfully establishing a leading domestic mRNA technology and industrialization platform. This initiative not only introduces a novel technical route for developing preventive vaccines but also creates a robust foundation for future therapeutic advancements, including tumor vaccines, protein replacement drugs, and In Vivo CAR-T therapies.<br><br>Building on its mRNA technology platform, the company has also obtained clinical trial approvals for its respiratory syncytial virus mRNA vaccine and freeze-dried shingles mRNA vaccine. Meanwhile, other therapeutic mRNA drugs are currently advancing through pre-clinical research stages.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Walvax Biotechnology's Subsidiary Secures Regulatory Approval for COVID-19 mRNA Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWalvax Biotechnology's Subsidiary Secures Regulatory Approval for COVID-19 mRNA Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-10 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Walvax Biotechnology Co.,Ltd.</b> (300142.SZ) has officially announced that its wholly-owned subsidiary, Yuxi Walvax Biotechnology Co., Ltd., received the \"COVID-19 mRNA Vaccine\" Drug Registration Certificate from the National Medical Products Administration on September 10, 2026.<br><br>Leveraging its mRNA platform technology, the company is positioned to continuously update and iterate new vaccines targeting prevalent strains as recommended by the World Health Organization (WHO) or China's disease control authorities. The newly approved vaccine is designed for use in individuals aged 18 years and above to prevent COVID-19.<br><br>This latest approval marks the third-generation COVID-19 mRNA vaccine developed by the company through iterative advancements in its mRNA platform. Since 2020, <b>Walvax Biotechnology Co.,Ltd.</b> has significantly increased its investment in mRNA technology, successfully establishing a leading domestic mRNA technology and industrialization platform. This initiative not only introduces a novel technical route for developing preventive vaccines but also creates a robust foundation for future therapeutic advancements, including tumor vaccines, protein replacement drugs, and In Vivo CAR-T therapies.<br><br>Building on its mRNA technology platform, the company has also obtained clinical trial approvals for its respiratory syncytial virus mRNA vaccine and freeze-dried shingles mRNA vaccine. Meanwhile, other therapeutic mRNA drugs are currently advancing through pre-clinical research stages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1158588840","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158588840","pubTimestamp":1789045687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Walvax Biotechnology Co.,Ltd. (300142.SZ) has officially announced that its wholly-owned subsidiary, Yuxi Walvax Biotechnology Co., Ltd., received the \"COVID-19 mRNA Vaccine\" Drug Registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300142":"沃森生物","BK0239":"医药制造","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BK0070":"员工持股","MRNY":"MRNA期权收益策略ETF-YieldMax","BK0077":"质押式回购","BK0046":"生物疫苗"},"translate_title":"Walvax Biotechnology 子公司获得 COVID-19 mRNA 疫苗监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300142":1,"MRNY":1,"MRNX":1},"content_text":"Walvax Biotechnology Co.,Ltd. (300142.SZ) has officially announced that its wholly-owned subsidiary, Yuxi Walvax Biotechnology Co., Ltd., received the \"COVID-19 mRNA Vaccine\" Drug Registration Certificate from the National Medical Products Administration on September 10, 2026.Leveraging its mRNA platform technology, the company is positioned to continuously update and iterate new vaccines targeting prevalent strains as recommended by the World Health Organization (WHO) or China's disease control authorities. The newly approved vaccine is designed for use in individuals aged 18 years and above to prevent COVID-19.This latest approval marks the third-generation COVID-19 mRNA vaccine developed by the company through iterative advancements in its mRNA platform. Since 2020, Walvax Biotechnology Co.,Ltd. has significantly increased its investment in mRNA technology, successfully establishing a leading domestic mRNA technology and industrialization platform. This initiative not only introduces a novel technical route for developing preventive vaccines but also creates a robust foundation for future therapeutic advancements, including tumor vaccines, protein replacement drugs, and In Vivo CAR-T therapies.Building on its mRNA technology platform, the company has also obtained clinical trial approvals for its respiratory syncytial virus mRNA vaccine and freeze-dried shingles mRNA vaccine. Meanwhile, other therapeutic mRNA drugs are currently advancing through pre-clinical research stages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}